U.S. FDA Grants Artera Breakthrough Device Designation for AI-Powered Software Transforming Prostate Cancer Care
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced to [...]
Artera Launches Registry Trial to Measure Real-World Impact and Outcomes of its Prostate Test
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced th [...]
The ArteraAI Prostate Test Enhanced with New Insights for Higher Risk Patients with Localized Prostate Cancer
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, has updated [...]
Artera Presenting Validation Data at 2025 ASCO Annual Meeting Highlighting How Multimodal AI Platform (MMAI) is Advancing Personalized Cancer Care
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announ [...]
Diagnexia and Artera Partner to Bring Groundbreaking AI Prostate Test to the UK
Diagnexia, the UK’s leading provider of AI-powered digital pathology diagnostic services, is thrilled to announce an exclusiv [...]
Phase 3 trial launches of ArteraAI Prostate test for treatment selection
The first patient has been enrolled in the phase 3 PROSTATE-IQ trial (NCT06274047), assessing the ability of the ArteraAI Pro [...]
Tempus Partners with Artera to Expand Personalized Prostate Cancer Treatment
Tempus, a leader in using artificial intelligence (AI) to advance precision medicine connected to over half of all practicing [...]
Artera’s Multimodal Artificial Intelligence Named Among TIME’s 2024 Best Inventions
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced th [...]
Artera Receives California Lab License, Expanding Access to its ArteraAI Prostate Test
Clinicians and patients in California can now access personalized, actionable insights to inform prostate cancer treatment de [...]